Arabic
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Evaluation of PKU Sphere in Maternal PKU

يمكن للمستخدمين المسجلين فقط ترجمة المقالات
الدخول التسجيل فى الموقع
يتم حفظ الارتباط في الحافظة
الحالةتجنيد
الرعاة
Vitaflo International, Ltd
المتعاونون
University College London Hospitals

الكلمات الدالة

نبذة مختصرة

This observational study aims to recruit females, aged 16 years and over, with phenylketonuria (PKU) or hyperphenylalaninemia (hyperphe) following dietary management advice pre-conception and/or during pregnancy, who are willing to take PKU sphere as part of their dietarty management.

وصف

The aim of this study is to observe dietary management and metabolic control in women taking PKU sphere pre-conceptually and/or during pregnancy. To do this the following data points will be captured:

- Blood spot phenylalanine and tyrosine levels to measure metabolic control

- Changes to dietary management and any adaptations arising from incorporating PKU Sphere

- Compliance/adherence of patients to their recommended amount of protein substitute prescription.

- Tolerance of PKU sphere with respect to gastrointestinal (GI) symptoms and pregnancy associated nausea and vomiting.

- Acceptability of concurrent protein substitute(s) (if applicable).

- Nutritional status and weight management.

- Routine standard of care data on the final pregnancy outcome and postpartum.

تواريخ

آخر التحقق: 01/31/2020
تم الإرسال لأول مرة: 10/06/2019
تم إرسال التسجيل المقدر: 01/06/2020
أول نشر: 01/12/2020
تم إرسال آخر تحديث: 02/02/2020
آخر تحديث تم نشره: 02/04/2020
تاريخ بدء الدراسة الفعلي: 07/28/2019
تاريخ الإنجاز الأساسي المقدر: 07/28/2021
التاريخ المتوقع لانتهاء الدراسة: 07/28/2021

حالة أو مرض

Maternal Phenylketonuria

التدخل / العلاج

Dietary Supplement: PKU sphere

مرحلة

-

مجموعات الذراع

ذراعالتدخل / العلاج
PKU sphere
PKU sphere (an FSMP) as per individual requirements determined by a dietitian.
Dietary Supplement: PKU sphere
PKU sphere is a Food for Special Medical Purposes (FSMP). This product is for use in the dietary management of phenylketonuria (PKU). It is a powdered, low phenylalanine medical food containing a balanced mix of GMP, essential and non-essential amino acids, carbohydrate, fat, vitamins, minerals, and DHA. It is available in 27g sachets providing 15g PE and contains 28mg Phe and 35g sachets providing 20g PE and contains 36mg Phe.

معايير الأهلية

الأعمار المؤهلة للدراسة 16 Years إلى 16 Years
الأجناس المؤهلة للدراسةFemale
طريقة أخذ العيناتNon-Probability Sample
يقبل المتطوعين الأصحاءنعم
المعايير

Inclusion Criteria:

- Diagnosis of phenylketonuria (PKU) or hyperphenylalaninemia (hyperphe) which requires dietary management during pre-conception and/or pregnancy.

- Aged 16 years and above.

- Following dietary management advice pre-conceptually and/or during pregnancy, aiming for phenylalanine levels of 120-250µmol/L.

- Prior positive PKU Sphere taste test completed as part of routine care.

- Chosen to take part or full requirement of protein substitute as PKU sphere pre-conceptually and/or during pregnancy.

- Willingly given, written, informed consent from patient.

- Participant is, in the opinion of the investigator, able to participate and can comply with the study protocol.

Exclusion Criteria:

- Conception of pregnancy without commencement of phe-restricted diet and blood phenylalanine not maintained within target range by 10 weeks' gestation.

- Patients with known soya, milk or fish allergies / intolerance.

- Intake of sapropterin dihydrochloride (Kuvan), pegvaliase or large neutral amino acids within 30 days prior to screening visit.

- Patients who are currently participating in, plan to participate in, or have participated in an interventional investigational drug, food or medical device trial within 30 days prior to screening visit.

النتيجة

مقاييس النتائج الأولية

1. Change in blood spot phenylalanine levels [Baseline, 1-2 times weekly during preconception (max. 2 years), 2-3 times weekly during pregnancy, one month postpartum.]

Measurement of fasting phenylalanine concentrations completed once (1) to twice (2) weekly preconception (which may last for an indeterminate amount of time), twice (2) to three (3) times weekly during pregnancy and one month postpartum. Collected as dried bloodspots on Guthrie cards in the patient's own home and posted to the hospital laboratory for analysis.

2. Change in blood spot tyrosine levels [Baseline, 1-2 times weekly during preconception (max. 2 years), 2-3 times weekly during pregnancy, one month postpartum.]

Measurement of fasting tyrosine concentrations completed once (1) to twice (2) weekly preconception (which may last for an indeterminate amount of time), twice (2) to three (3) times weekly during pregnancy and one month postpartum. Collected as dried bloodspots on Guthrie cards in the patient's own home and posted to the hospital laboratory for analysis.

3. Change in adherence to study product intake [Every 12 weeks from baseline during preconception (max. 2 years) and pregnancy until the end of the pregnancy]

3-day diary recording compliance/adherence of patients to their prescribed amount of protein substitute.

4. Participants' gastrointestinal adverse events [Throughout the study until one month postpartum]

Participant to report any gastrointestinal (GI) symptoms and pregnancy-associated nausea and vomiting while consuming PKU Sphere.

5. Change in weight [Baseline, every 24 weeks during preconception (max. 2 years) and pregnancy, one month postpartum]

Weight (kg)

6. Change in plasma amino acid profile [Baseline, all routine results during preconception (max. 2 years) and pregnancy, one month postpartum]

Plasma amino acid profile

7. Change in plasma micronutrient profile [Baseline, all routine results during preconception (max. 2 years) and pregnancy, one month postpartum]

Plasma micronutrient profile

8. Pregnancy outcome [End of pregnancy]

Standard of care data on the outcome of the pregnancy

انضم إلى صفحتنا على الفيسبوك

قاعدة بيانات الأعشاب الطبية الأكثر اكتمالا التي يدعمها العلم

  • يعمل في 55 لغة
  • العلاجات العشبية مدعومة بالعلم
  • التعرف على الأعشاب بالصورة
  • خريطة GPS تفاعلية - ضع علامة على الأعشاب في الموقع (قريبًا)
  • اقرأ المنشورات العلمية المتعلقة ببحثك
  • البحث عن الأعشاب الطبية من آثارها
  • نظّم اهتماماتك وابقَ على اطلاع دائم بأبحاث الأخبار والتجارب السريرية وبراءات الاختراع

اكتب أحد الأعراض أو المرض واقرأ عن الأعشاب التي قد تساعد ، واكتب عشبًا واطلع على الأمراض والأعراض التي تستخدم ضدها.
* تستند جميع المعلومات إلى البحوث العلمية المنشورة

Google Play badgeApp Store badge